(1) Documents and emails describing potential conflicts of interest in any members of any committee that recommended a vaccine.
(2) Documents and emails describing the duration of protection by vaccines recommended by the CDC or ACIP.
(3) Documents and emails describing the safety and efficacy testing of the influenza vaccine.
(4) Documents and emails describing long-term safety studies of children and adults who have received five or more annual doses of the influenza vaccine, including incidence of allergic manifestations (asthma, food allergies, and eczema) and autoimmune diseases (including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis) in vaccinated versus unvaccinated groups.
(5) Documents and emails describing tests for possible viral or bacterial contaminants in vaccines.
(6) Documents and emails describing safety testing for thimerosal in children and adults.
(7) Documents and emails describing any testing of thimerosal and other vaccine components for potential adjuvant effects.
(8) Documents and emails describing investigations of the potential for any components with adjuvant-like effect for inducing allergies to vaccine components or antigens to which recipient is coincidentally exposed (such as peanuts or pollen).
(9) Documents and emails describing absenteeism rates in schoolchildren and health care workers who have or have not received the influenza vaccine, including time off for vaccine adverse reactions.
(10) Documents and emails describing the carriage rate of respiratory viruses, including the influenza virus, in vaccinated versus unvaccinated personnel.
(11) Documents and emails comparing the effectiveness of immunization of personnel versus other methods of protecting patients against acquiring influenza in-house: for example, ultraviolet lights to sanitize air, requiring visitors to use hand hygiene and/or wear masks, and more stringent housekeeping protocols as for disinfecting surfaces.
(12) Documents and emails describing the susceptibility to novel strains of influenza in personnel immunized with the usual annual vaccine compared with those not so immunized.
Date range: 01/01/2008 through 04/01/2012.
Maximum amount authorized as a fee: $250. Request for fee waiver or reduction:
Request a fee waiver because these requested documents would “contribute significantly to public understanding” of the safety and efficacy of vaccines considered by the CDC. Vaccines are of enormous public concern and this request relates to advancing public knowledge about this issue. This request is not for any commercial interest. Instead, this request is being submitted on behalf of a non-profit physician group, the Association of American Physicians & Surgeons, which is an additional reason for granting a fee waiver or reduction in fees.
